Cancer Research Institute Ghent Ghent Belgium

CCRI St Anna Children's Cancer Research Institute Vienna Austria

Centre Hospitalier Universitaire de Liège Liege Belgium

Children's Cancer Institute Australia Lowy Cancer Research Centre University of NSW Randwick NSW Australia

CLIP Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Computational Biology Group Precision Nutrition and Cancer Research Program IMDEA Food Institute Madrid Spain

Computational Biology Leibniz Institute on Ageing Fritz Lipmann Institute Jena Germany

Department of Genetics Robert Debré Hospital and University of Paris Paris France

Department of Oncology St Jude Children's Research Hospital Memphis TN USA

Department of Paediatrics The Chinese University of Hong Kong Shatin Hong Kong

Department of Pediatric Hemato oncology and Stem Cell Transplantation Ghent University Hospital Ghent Belgium

Department of Pediatric Hematology and Oncology Research National Research Institute for Child Health and Development Tokyo Japan

Department of Pediatric Hematology and Oncology St Anna Children's Hospital Medical University of Vienna Vienna Austria

Department of Pediatric Hematology and Oncology University Medical Center Hamburg Hamburg Germany

Department of Pediatric Oncology and Hematology Medical University of Lodz Lodz CA Poland

Department of Pediatrics Christian Albrechts University Kiel and University Medical Center Schleswig Holstein Kiel Germany

Department of Pediatrics Kyoto Prefectural University of Medicine Kyoto Japan

Erasmus MC Sophia Children's Hospital Department of Pediatric Oncology Hematology Rotterdam Netherlands

Institute of Human Genetics Medical School Hannover Hannover Germany

Interfant Trial Data Center School of Medicine and Surgery University of Milan Bicocca Monza Italy

Leukaemia Research Cytogenetics Group Wolfson Childhood Cancer Research Centre Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne United Kingdom

Oncode Institute Utrecht Netherlands

Princess Máxima Center for Pediatric Oncology Utrecht Netherlands

Tettamanti Research Center Pediatric Clinic University of Milan Bicocca Monza Italy

Zobrazit více v PubMed

Li JF, Dai YT, Lilljebjorn H, Shen SH, Cui BW, Bai L, et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci USA. 2018;115(Dec):E11711–20. doi: 10.1073/pnas.1814397115. PubMed DOI PMC

Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51(Feb):296–307. doi: 10.1038/s41588-018-0315-5. PubMed DOI PMC

Hormann FM, Hoogkamer AQ, Beverloo HB, Boeree A, Dingjan I, Wattel MM, et al. NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2. Haematologica. 2019;104(Oct):e455–9. doi: 10.3324/haematol.2018.206961. PubMed DOI PMC

Ueno H, Yoshida K, Shiozawa Y, Nannya Y, Iijima-Yamashita Y, Kiyokawa N, et al. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2020;4(Oct):5165–73. doi: 10.1182/bloodadvances.2019001307. PubMed DOI PMC

Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016;7(Nov):13331. doi: 10.1038/ncomms13331. PubMed DOI PMC

Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(Apr):330–7. doi: 10.1038/ng.3230. PubMed DOI PMC

De Lorenzo P, Moorman AV, Pieters R, Dreyer ZE, Heerema NA, Carroll AJ, et al. Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements. Leukemia. 2014;28(Feb):428–30. doi: 10.1038/leu.2013.280. PubMed DOI PMC

Pincez T, Landry JR, Roussy M, Jouan L, Bilodeau M, Laramee L, et al. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2020;59(Feb):125–30. doi: 10.1002/gcc.22808. PubMed DOI

Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(Jul):240–50. doi: 10.1016/S0140-6736(07)61126-X. PubMed DOI

Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 Protocol: results from an international phase III randomized study. J Clin Oncol. 2019;37(Sep):2246–56. doi: 10.1200/JCO.19.00261. PubMed DOI

Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34(Aug):2591–601. doi: 10.1200/JCO.2015.64.6364. PubMed DOI

Stutterheim J, van der Sluis IM, de Lorenzo P, Alten J, Ancliffe P, Attarbaschi A, et al. Clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukemia treated on the Interfant-06 Protocol. J. Clin. Oncol. 2021;39(6):652–62. PubMed PMC

Martens JH, Stunnenberg HG. BLUEPRINT: mapping human blood cell epigenomes. Haematologica. 2013;98(Oct):1487–9. doi: 10.3324/haematol.2013.094243. PubMed DOI PMC

Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C, et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010;29(Sep):2943–52. doi: 10.1038/emboj.2010.176. PubMed DOI PMC

Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Moricke A, Locatelli F, et al. Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000) J Clin Oncol. 2018;36(Jan):244–53. doi: 10.1200/JCO.2017.74.4946. PubMed DOI

PAX5::AUTS2 childhood B-ALL: a relapse-prone genetic subtype with frequent central nervous system involvement and a poor outcome